Physicochemical Properties
| Molecular Formula | C15H14NBR |
| Molecular Weight | 288.18236 |
| Exact Mass | 287.031 |
| CAS # | 677746-25-7 |
| PubChem CID | 24858056 |
| Appearance | White to off-white solid powder |
| LogP | 4.086 |
| Hydrogen Bond Donor Count | 0 |
| Hydrogen Bond Acceptor Count | 1 |
| Rotatable Bond Count | 1 |
| Heavy Atom Count | 17 |
| Complexity | 278 |
| Defined Atom Stereocenter Count | 0 |
| InChi Key | KABXKWWJTYSDTD-UHFFFAOYSA-N |
| InChi Code | InChI=1S/C15H14BrN/c1-17(2)13-4-6-15-11(9-13)7-10-8-12(16)3-5-14(10)15/h3-6,8-9H,7H2,1-2H3 |
| Chemical Name | 7-bromo-N,N-dimethyl-9H-fluoren-2-amine |
| HS Tariff Code | 2934.99.9001 |
| Storage |
Powder-20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition | Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs) |
Biological Activity
| ln Vitro | K 01-162 (1 μM; 24 hours) decreases intracellular AβO levels [2]. K 01-162 (0.78-50 μM; 5 minutes) blocks the synaptic binding activity of AβO in mouse hippocampus neurons [2]. |
| ln Vivo | K 01-162 (100 μM; 0.25 μL/h intracerebroventricular infusion for 2 weeks) can reduce the body's amyloid load [2]. |
| Cell Assay |
Western Blot Analysis[2] Cell Types: MC65 Cell Line Tested Concentrations: 1 μM Incubation Duration: 24 hrs (hours) Experimental Results: diminished levels of SDS-stabilized Aβ trimers and larger aggregates. |
| Animal Protocol |
Animal/Disease Models: 5xFAD mice with cerebral Aβ amyloidosis [2] Doses: 100 μM Route of Administration: intracerebroventricular infusion; 100 μM 0.25 μL/h; continued for 2 weeks Experimental Results: No obvious toxicity was caused, and hippocampus The amyloid burden was Dramatically diminished to 50% of simulated treatment levels. |
| References |
[1]. Alzheimer's disease drug candidates stabilize A-β protein native structure by interacting with the hydrophobic core. Biophys J. 2011 Feb 16;100(4):1076-82. [2]. Candidate anti-A beta fluorene compounds selected from analogs of amyloid imaging agents. Neurobiol Aging. 2010 Oct;31(10):1690-9. |
Solubility Data
| Solubility (In Vitro) | DMSO : ~14.29 mg/mL (~49.59 mM) |
| Solubility (In Vivo) |
Solubility in Formulation 1: 1.43 mg/mL (4.96 mM) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), suspension solution; with sonication. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 14.3 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 1.43 mg/mL (4.96 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 14.3 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. Solubility in Formulation 3: ≥ 1.43 mg/mL (4.96 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 14.3 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.4701 mL | 17.3503 mL | 34.7005 mL | |
| 5 mM | 0.6940 mL | 3.4701 mL | 6.9401 mL | |
| 10 mM | 0.3470 mL | 1.7350 mL | 3.4701 mL |